Start Phase 3 trial in patients with recurrent platinum-resistant ovarian cancer
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Nov 2021
- Due
- 31 Mar 2022
- Delivered
- June 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 trial in patients with recurrent platinum-resistant ovarian cancer to start in the first quarter of 2022”
What we found
Evidence strength A What the grades mean
The company committed to starting the Phase 3 trial in Q1 2022, but filings confirm the trial (ROSELLA) did not begin until June 2022.
-
A Corcept Therapeutics Inc. 10-Q filed 2022-08-04
“In June 2022, we began a pivotal Phase 3 trial (“ROSELLA”).” ✓ confirmed on the page
Market reaction: the shares moved -0.9% against the S&P 500 over the three sessions around the disclosure (3 Aug 2022 to 8 Aug 2022). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 2 versions
-
Version 1 · original · stated 3 Nov 2021
Deadline 31 Mar 2022 (“first quarter of 2022”)
-
Version 2 · stated 15 Feb 2022
Deadline 30 Jun 2022 (“second quarter 2022”) · wording expected
“Phase 3 trial planned to start second quarter 2022”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- Phase 3 trial
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CORT-002836 · Corrections policy